{"ticker": {"uuid": "2b0e706f-1662-4239-aa1d-1582ee536278", "symbol": "PULM", "name": "Pulmatrix Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Pulmatrix (NASDAQ: PULM) to Merge with Eos; 75.2M Shares to Be Issued", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxQd3FkU29HOEFUbm9abjBtdURIRjdUekdlbVZ3WTZ1ZHVqR0tNZTYzZ0N2VVV0eU1sU3BwTDZRQXZKVVJ6Mlc3LXIzTkJfQmVDYld5Wk1sN3doQnN1bGo0MGJMSUVSWFdRVE01eWhsUmxIWUVPRzRvRzAxeXlTcVFBclZhalZpTmlUTC0zcVBWZy0zZVdlRktEcFNmbXNHRWdVSHFDSHZmb3NNZFlEZkpzVjVuYw?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-09T20:06:49+00:00", "published_display": "09 Jul 2026 20:06", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulmatrix | 425: Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions - moomoo", "summary": "This article states that Pulmatrix has filed under Securities Act Rule 425. This filing is in connection with various prospectuses and communications related to business combination transactions. The document itself is not provided in this snippet.", "url": "https://www.moomoo.com/news/notice/306751131/pulmatrix-425-filing-under-securities-act-rule-425-of-certain", "source_name": "Moomoo", "published_at": "2026-07-07T09:40:04", "published_display": "07 Jul 2026 09:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PULM - Pulmatrix Inc Latest SEC Filings", "summary": "This article provides the latest SEC filings and detailed financial data for Pulmatrix Inc. (PULM). It includes key financial metrics, stock performance, insider ownership, institutional ownership, and analyst recommendations, offering a comprehensive overview of the company's cu", "url": "https://finviz.com/stock?t=PULM&ta=1&p=d&ty=lf&page=16", "source_name": "Finviz", "published_at": "2026-07-06T19:39:46", "published_display": "06 Jul 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Pulmatrix, Inc. \u2013 NASDAQ:PULM", "summary": "This article displays the \"Enterprise value to EBITDA forward\" metric for Pulmatrix, Inc. (NASDAQ: PULM) on TradingView. It presents financial data for the company, noting the market status as closed with no trades. The page also provides general information about TradingView's o", "url": "https://www.tradingview.com/symbols/NASDAQ-PULM/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-07-06T00:41:23", "published_display": "06 Jul 2026 00:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulmatrix Inc Actuals & Estimates (NASDAQ:PULM)", "summary": "This article provides an overview of Pulmatrix, Inc. (NASDAQ: PULM) stock, including its current price, market capitalization, historical performance, and financial data. It highlights the company's financial results, such as net income for the last quarter, and upcoming earnings", "url": "https://www.tradingview.com/symbols/NASDAQ-PULM/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T17:39:51", "published_display": "26 Jun 2026 17:39", "sentiment": "negative", "sentiment_pct": 40, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Pulmatrix, Inc. \u2013 NASDAQ:PULM", "summary": "This article provides the \"Price to earnings forward\" value for Pulmatrix, Inc. (NASDAQ: PULM). The value itself is not displayed, but the context indicates it's a financial metric for the pharmaceutical company. The page also lists various data providers for market and reference", "url": "https://www.tradingview.com/symbols/NASDAQ-PULM/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T10:11:53", "published_display": "25 Jun 2026 10:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulmatrix Inc (PULM) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Pulmatrix Inc (PULM), focusing on its price momentum, support and resistance levels, and insights from various technical indicators and moving averages. As of June 25, 2026, PULM shows a strong price momentum score and is trading with", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-pulm/technical", "source_name": "TradingKey", "published_at": "2026-06-25T02:11:27", "published_display": "25 Jun 2026 02:11", "sentiment": "positive", "sentiment_pct": 60, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulmatrix Inc (PULM) Valuation: PE, PB & Fair Value Analysis", "summary": "The article provides a valuation analysis of Pulmatrix Inc (PULM), stating its current valuation score is 7.17, ranking 255 out of 389 in the Biotechnology & Medical Research industry. It notes the company's P/E ratio is -1.18, significantly below its recent high and above its re", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-pulm/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-19T00:39:46", "published_display": "19 Jun 2026 00:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulmatrix Inc (PULM) Financial Health: Profitability & Balance Sheet Analysis", "summary": "Pulmatrix Inc (PULM) currently has a financial score of 6.80, placing it 210th out of 388 companies in the Biotechnology & Medical Research industry. The analysis indicates robust financial status but low operating efficiency. Several key financial data points such as total asset", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-pulm/financial-health", "source_name": "TradingKey", "published_at": "2026-06-18T09:10:42", "published_display": "18 Jun 2026 09:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulmatrix Inc (PULM) Risk Assessment: Volatility, Financial Risk & Investment Risk", "summary": "This article provides a detailed risk assessment for Pulmatrix Inc (PULM), highlighting its volatility, financial risk, and investment risk. It notes the stock's beta of 1.95, indicating high sensitivity to market movements, and presents various metrics such as maximum drawdown, ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-pulm/risk-assesment", "source_name": "TradingKey", "published_at": "2026-06-18T08:18:26", "published_display": "18 Jun 2026 08:18", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulmatrix Inc (PULM) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article from TradingKey provides an earnings forecast for Pulmatrix Inc (PULM), noting that no earnings forecast score is currently available for the company. It highlights that the Biotechnology & Medical Research industry's average score is 8.13 and indicates that relevant", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-pulm/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T03:18:26", "published_display": "18 Jun 2026 03:18", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulmatrix Inc (PULM) Institutional Confidence", "summary": "Pulmatrix Inc (PULM) currently has an institutional shareholding score of 3.00, placing it 193rd out of 389 in the Biotechnology & Medical Research industry. The institutional shareholding proportion is 10.12%, an 8.89% increase quarter-over-quarter. James Simons is the largest i", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-pulm/sentiment", "source_name": "TradingKey", "published_at": "2026-06-17T23:40:29", "published_display": "17 Jun 2026 23:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulmatrix Inc (PULM) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article from TradingKey attempts to provide a revenue breakdown for Pulmatrix Inc (PULM), covering business segments, regional revenue, and profit contribution. However, it states that the relevant data has not yet been disclosed by the company. The page displays Pulmatrix I", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-pulm/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T18:08:59", "published_display": "17 Jun 2026 18:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulmatrix (NASDAQ: PULM) posts 2025 loss as Cullgen merger to give Cullgen 96.4%", "summary": "Pulmatrix, Inc. has amended its 2025 annual report, revealing a net loss of $5.162 million and zero revenue, a significant decrease from 2024 due to the conclusion of its Cipla collaboration and reduced operating expenses. The company's future hinges on its pending merger with Cu", "url": "https://www.stocktitan.net/sec-filings/PULM/10-k-a-pulmatrix-inc-amends-annual-report-520cd2089086.html", "source_name": "Stock Titan", "published_at": "2026-06-16T20:39:20", "published_display": "16 Jun 2026 20:39", "sentiment": "negative", "sentiment_pct": 19, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Preclinical data: PTC-2105 boosts lean mass; Pulmatrix (NASDAQ: PULM) merger on track", "summary": "Pulmatrix (NASDAQ: PULM) and Eos SENOLYTIX have released preclinical data for MitoXcel\u2122 geropeptide PTC-2105, showing it significantly boosts lean mass, reduces fat, and improves physical function in animal studies, with prolonged benefits compared to GLP-1 comparators. The compa", "url": "https://www.stocktitan.net/sec-filings/PULM/425-pulmatrix-inc-business-combination-communication-696513b8faa0.html", "source_name": "Stock Titan", "published_at": "2026-06-05T12:08:47", "published_display": "05 Jun 2026 12:08", "sentiment": "positive", "sentiment_pct": 67, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulmatrix (PULM) registers 490,910 shares for resale including 36,364 dividends", "summary": "Pulmatrix, Inc. (PULM) has registered 490,910 shares of Common Stock for resale, including 36,364 Dividend Shares, stemming from the conversion of 1,000 Series B Convertible Preferred Shares. These shares, which convert at $2.20 and carry an 8% annual dividend payable in Common S", "url": "https://www.stocktitan.net/sec-filings/PULM/s-3-pulmatrix-inc-shelf-registration-statement-daa3487021cd.html", "source_name": "Stock Titan", "published_at": "2026-06-04T10:39:05", "published_display": "04 Jun 2026 10:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PULM - Pulmatrix Inc Stock Price and Quote", "summary": "This page provides a comprehensive overview of Pulmatrix Inc. (PULM) stock, including its latest stock price, financial metrics, and price performance. It also lists recent news and press releases from the company, detailing financial results, merger agreements, clinical trial up", "url": "https://finviz.com/stock?t=PULM", "source_name": "Finviz", "published_at": "2026-06-01T17:09:40", "published_display": "01 Jun 2026 17:09", "sentiment": "negative", "sentiment_pct": 38, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulmatrix Inc. (PULM) Faces Modest Decline as Stock Tests Key Support Levels - Call Flow Alert", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxONUpVZUFOajdUTHBUZGFTT3FIZGpKMWdrWTNnTDM1bVZEclBRQU1qVkRBaXRiUTVEQ2FFakxYMFNpbjVnTkhaQnJDUU1wWUFJb3lNQkdYSU9xeEl1MkJTWFI0RWQyMjZkVTN6MEZvdk42d3FNNjQ2M2ZlM0hzT011bEVCY3hETXU3eFNqNXZtN0dPTEdkWkQtVUpfUTFZS20tMnlSNzBqR01SWUw1UUpDeEVBVHRmR052?oc=5", "source_name": "dars.gov.et", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PULM: Merger with Eos SENOLYTIX announced; Q1 net loss narrows, cash at $3.3M", "summary": "Pulmatrix (PULM) has announced a merger with Eos SENOLYTIX and successfully closed a $1 million private placement. In the first quarter of 2026, the company's net loss narrowed to $1.2 million due to reduced expenses, and it reported $3.3 million in cash reserves. Clinical develo", "url": "https://www.tradingview.com/news/urn:summary_document_report:quartr.com:3335777:0-pulm-merger-with-eos-senolytix-announced-q1-net-loss-narrows-cash-at-3-3m/", "source_name": "TradingView", "published_at": "2026-05-16T09:10:53", "published_display": "16 May 2026 09:10", "sentiment": "positive", "sentiment_pct": 62, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Press Release: Pulmatrix Announces First Quarter 2026 Financial Results", "summary": "This press release from Pulmatrix announces its financial results for the first quarter of 2026. It will provide key financial figures, operational highlights, and potentially an outlook for the remainder of the year. Investors and stakeholders can expect to find details regardin", "url": "https://www.moomoo.com/news/post/70096842/press-release-pulmatrix-announces-first-quarter-2026-financial-results", "source_name": "Moomoo", "published_at": "2026-05-15T19:09:33", "published_display": "15 May 2026 19:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulmatrix Releases Q1 2026 Financial Results", "summary": "Pulmatrix, Inc. (PULM) reported a narrower loss for the first quarter of 2026, with a diluted loss per share of $0.32, showing an improvement from the prior year. The biopharmaceutical company is advancing its pipeline of inhaled therapeutic products for migraine prevention and r", "url": "https://news.alphastreet.com/pulmatrix-releases-q1-2026-financial-results/", "source_name": "AlphaStreet", "published_at": "2026-05-15T14:09:33", "published_display": "15 May 2026 14:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulmatrix Announces First Quarter 2026 Financial Results", "summary": "Pulmatrix, Inc. announced its first quarter 2026 financial results, highlighting a merger agreement with Eos SENOLYTIX and a private placement of preferred stock. The company is actively seeking to out-license or monetize its clinical assets, including iSPERSE\u2122 technology and pro", "url": "https://www.prnewswire.com/news-releases/pulmatrix-announces-first-quarter-2026-financial-results-302773027.html", "source_name": "PR Newswire", "published_at": "2026-05-15T12:09:33", "published_display": "15 May 2026 12:09", "sentiment": "positive", "sentiment_pct": 61, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulmatrix, Inc. 1Q 2026: Net loss $(1.17M), EPS $(0.32) \u2014 10-Q Summary", "summary": "Pulmatrix, Inc. reported a first-quarter 2026 net loss of $(1.17M), or $(0.32) per share, showing an improvement from the prior year. The company is undergoing a strategic merger with Eos, has paused clinical development to explore monetization options for its pipeline programs (", "url": "https://www.tradingview.com/news/tradingview:d632313770c20:0-pulmatrix-inc-1q-2026-net-loss-1-17m-eps-0-32-10-q-summary/", "source_name": "TradingView", "published_at": "2026-05-15T12:09:33", "published_display": "15 May 2026 12:09", "sentiment": "positive", "sentiment_pct": 60, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulmatrix reports Q1 2026 net loss $1.17M, cash $3.3M and announces merger agreement with Eos SENOLYTIX", "summary": "Pulmatrix reported a Q1 2026 net loss of $1.17 million and held $3.3 million in cash by March 31, 2026. The company announced a merger agreement with Eos SENOLYTIX, expected to close in Q3 2026, and a $1.0 million private placement of preferred stock. Clinical development is curr", "url": "https://www.tradingview.com/news/tradingview:fa40c9fc90de0:0-pulmatrix-reports-q1-2026-net-loss-1-17m-cash-3-3m-and-announces-merger-agreement-with-eos-senolytix/", "source_name": "TradingView", "published_at": "2026-05-15T12:09:33", "published_display": "15 May 2026 12:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulmatrix (NASDAQ: PULM) Q1 loss, $1M raise and Eos merger plan", "summary": "Pulmatrix (NASDAQ: PULM) reported a Q1 2026 net loss of $1.2 million, an improvement from $1.8 million a year prior, as operating expenses decreased. The company is actively pursuing a merger with Eos SENOLYTIX, expected to close in Q3 2026, and has raised $1.0 million through a ", "url": "https://www.stocktitan.net/sec-filings/PULM/8-k-pulmatrix-inc-reports-material-event-a44e5335ae08.html", "source_name": "Stock Titan", "published_at": "2026-05-15T12:09:33", "published_display": "15 May 2026 12:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulmatrix (PULM) Q1 2026 shows tight cash, Eos merger and 94% pro forma dilution", "summary": "Pulmatrix, Inc. (PULM) reported a Q1 2026 net loss of $1.2 million, an improvement from the previous year, primarily due to reduced operating expenses and paused R&D. The company concluded its first quarter with $3.3 million in cash and highlighted substantial doubt about its abi", "url": "https://www.stocktitan.net/sec-filings/PULM/10-q-pulmatrix-inc-quarterly-earnings-report-4c249e156f4d.html", "source_name": "Stock Titan", "published_at": "2026-05-15T12:09:33", "published_display": "15 May 2026 12:09", "sentiment": "negative", "sentiment_pct": 20, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Number of shareholders of Pulmatrix, Inc. \u2013 NASDAQ:PULM", "summary": "This article provides general financial information for Pulmatrix, Inc. (NASDAQ: PULM) as found on TradingView. It indicates that the current market status is closed and offers navigation to various financial and community features related to the company. The core content focuses", "url": "https://www.tradingview.com/symbols/NASDAQ-PULM/financials-statistics-and-ratios/number-of-shareholders/", "source_name": "TradingView", "published_at": "2026-05-10T10:39:29", "published_display": "10 May 2026 10:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulmatrix (Nasdaq:PULM) - Stock Analysis", "summary": "This Simply Wall St analysis provides an overview of Pulmatrix (PULM), a biopharmaceutical company with a market cap of US$5.0m. The report summarizes its valuation, growth prospects, past performance, financial health, and recent news including a recent acquisition agreement by ", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-pulm/pulmatrix", "source_name": "Simply Wall Street", "published_at": "2026-05-08T06:38:58", "published_display": "08 May 2026 06:38", "sentiment": "negative", "sentiment_pct": 29, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulmatrix Announces Second Quarter 2025 Financial Results and Divestment Plan for Inhalation Assets", "summary": "Pulmatrix announced its second quarter 2025 financial results and a plan to divest its inhalation assets. This news was delivered by Quantisnow, a real-time market data and news platform for retail investors. The company, trading under the symbol PULM, is in the healthcare sector", "url": "https://www.quantisnow.com/insight/pulmatrix-announces-second-quarter-2025-financial-results-and-divestment-plan-6149353", "source_name": "Quantisnow", "published_at": "2026-04-29T16:40:11", "published_display": "29 Apr 2026 16:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulmatrix closes $1M preferred stock placement with Eos affiliate By Investing.com", "summary": "Pulmatrix, Inc. (NASDAQ:PULM) has secured approximately $1 million through a private placement of Series B Convertible Preferred Stock with an affiliate of Eos SENOLYTIX, Inc. This strategic move is part of Pulmatrix's planned merger with Eos, with the preferred stock convertible", "url": "https://za.investing.com/news/company-news/pulmatrix-closes-1m-preferred-stock-placement-with-eos-affiliate-93CH-4222747", "source_name": "Investing.com South Africa", "published_at": "2026-04-26T03:38:44", "published_display": "26 Apr 2026 03:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Pulmatrix Announces Closing of Preferred Stock Transaction as Part of Planned Merger", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1wFBVV95cUxOMjUzb01IZUJjRlhfd2RzTlVTaURJMkIzeFpXdWl4OGs4VDFlOTZDZXUtXzc5dVJSbXlTNFFmUVZhNlduQm1POTNTTk1Mb3ZFU0t4QWlBQzZpYmI5b3dubHZWQkNVUW04cjlTQkVDUnhabWVlLUtWNWpoMmlsaUg0UXA4NVg1UkppNWljbHkyQ1R4QTJaMW9yOGdRRGdYVmkzamJnVTB2TEdTYzF0cmNHTi1BZndFQi1aZDVpcC0wYmZSZUQ3YV9wZ1JVTVNBc2hIZXhzczFCNA?oc=5", "source_name": "PR Newswire", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "PULM Stock Alert: Halper Sadeh LLC is Investigating Whether Pulmatrix, Inc. is Obtaining a Fair Price for its Shareholders", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiAJBVV95cUxOY3N0NUhfT1lfUzhraXlIb1NnUUpCVHZIdndabXQ3OTlqTklJVTZHcUdkLUVVRk45dUR4YnRGUG1GVTdVR3pyWDNxbEJuMG13dmxzVmtjQ096aVI1SXRMOUNjbVVUYkw1U0c0R1BjM0RSREYyd0lVUjN3djF4b2pVcGFHd1dDY1hKalVHYWRhTl9NcHYtNWM2X0RwRV82dGVEWHdxdXczZmwxQk9YYkRUeGpTUWVkMEVGbU00UF9HM2ZKMnlCQURjRmxpR3BOM1BzM09BaFF2UF9wNWl6c3FpLXR4NXZ0V3R1NjJOSWZMeEh4SkI4S0VhSXp1RDh6LTJ2YmFYRnMxMVY?oc=5", "source_name": "Business Wire", "published_at": "2026-04-13T07:00:00+00:00", "published_display": "13 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "What Just Happened to Pulmatrix (PULM) Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMigwFBVV95cUxQcHdIdDNVNk1IZV95QllwaVBZYXNzZUVmSU5yM2t6Ry1zSWxGRjB2V1dyMnBlNkFUd3ZDWTBwSklrRnk3eE1kelk4YzJYU2FKRjVNcTNZQlowUUtSd0dJbnVya1lXeDVNQ1BfTnFCZWUydE5QZFRCTlNPREhaZHFWUDJNMA?oc=5", "source_name": "Kavout | AI", "published_at": "2026-03-27T01:06:46+00:00", "published_display": "27 Mar 2026 01:06", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulmatrix and Eos SENOLYTIX Announce Merger Agreement to Advance Novel Mitochondrial Therapies to Improve Healthspan", "summary": "", "url": "https://news.google.com/rss/articles/CBMiggJBVV95cUxOdjFzWF9uT0paSHlhaHo1ZHJBWlNiQUZ4QWJIbzZmNjFkWHlxYlVGWC1xV05ZcUJiRzU3ZVJOd2FjNVBlWThGWFhNTDJoR1VPSXJiaUEwTDBOR0U4NUw4ejJGQXdMUFBUczdTbWdJeERLUWNjT3Y4X3FobkZteEYyc0NDVXQ1RTVWcnBfOGE2d1hld29udUxURFRMQXBJRzc5UFI0WkJHUEh5NVdmRWlMclZ5SUhlc3R6VVIzN3M1MlNobll2OHM4NXo0VHFCaE10SDFxRlhmSy1wUWFhRlE3akdDNkNRbnpsdUhhUVVFSGlDa0gyWXZkWUtpQi1EYTY5Snc?oc=5", "source_name": "PR Newswire", "published_at": "2026-03-26T07:00:00+00:00", "published_display": "26 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulmatrix Pursues New Reverse Merger After Cullgen Termination", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3wFBVV95cUxPZW9jcG9qMDR2bTA5V2hFc25idVZKc1RJVnFMQTA0M0lMZldUR1VEMjUzckNIVXJKUGNiUEd4QWttdWhyalcxTElrMXF5di02Tnh2V29oY0U4cE45cWRhMVJ2SzNaZDhQbjFmSER1Q2xUN0Y3NnhlWkF2TFNpZ1RFZzA2WW4yZndUNEJfNGdkbDNjY1RQQ3RJSnZULWVOS2huRm5iS1VBdkpuWm51TVpJMzg1UWdmZjZOWVA2N3R2U25VU3pTdnR3MGwzYTliNFBTN082QkQwdERZYXV0d3VZ?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-03-03T08:00:00+00:00", "published_display": "03 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulmatrix Shares Dive As Privately-Held Pharma Company Chooses To Merge With Gyre Therapeutics Instead", "summary": "", "url": "https://news.google.com/rss/articles/CBMi-gFBVV95cUxNODNCTkJBNVEtWi1mQlN5ZmZFdHNmQVNBZ0VoNU0tY3dBQmtlNlFoOEFmR0J5b3ktb1pMdl80VEIwSlR6bVJETEpLQXV4UHJGM1ZuSG5yc2Jqcno1MUdPenBXa2dNdlJHZ0MxTTB6UnNlbkxidFNFbFA2cFVYYVA2R2lPRTJPUkNCMXFfRVVGb2JveTY0dmF0VDFURVA3S2RMNU41R2JzSUFtVUtDOU0xdWNHOUpOWFBPUmxaNU41cmlvUmp2OVVjUnhJcWFicGJqVEIzUDJ5d3dsWVZjRkoyUHoxckFTcmJyak1VcXctSEJFRU5ZcktzYlJR?oc=5", "source_name": "Stocktwits", "published_at": "2026-03-02T08:00:00+00:00", "published_display": "02 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulmatrix Announces Termination of Prior Planned Merger and Continues Pursuit of Alternative Merger Opportunities", "summary": "", "url": "https://news.google.com/rss/articles/CBMi_gFBVV95cUxPTEwxNXduT1NGNVVxZzJOTjhNYlpqd2xZM2ZJRUNaWnRiWnVOTGplQksyaEhQUENHd0RmaWZKWHFSS051MmJadERsWEZNVzVRSmVOcGRmNDVac2Y4UGZYM2tuejZhNGN1cHJYU3dVcFp3RDRTMlpyb1M0VkZwSnhZOEs3U0JQM0F2OW1UekZKLVB5YnlhQk1SdW1JQzBqYi1FZm12QmRzb210a2hVd255VmVCb0owSWRhcDVySC1hOVBnMUQ5Sk83SFlfLXo1V3FVRXlWLTgtWEhvYXJiOHo0TlY0UVZEX3ZMcFc1VTc5ajlsakx4MXZoVE1ua1d2QQ?oc=5", "source_name": "PR Newswire", "published_at": "2026-03-02T08:00:00+00:00", "published_display": "02 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulmatrix and Cullgen Continue to Pursue Merger While Granting Each Other Waivers to Explore Alternatives", "summary": "", "url": "https://news.google.com/rss/articles/CBMi8wFBVV95cUxNMmhpOGczUW1jV1dpUV9sVjdWVF9sM2hKN1hPWHo3a1JrTzZseHJ5MEY0X1BWRC1RQnNUc2lKc1Z6ZkVwTV94dUdjOV9lWDljR1duQTA5TGU4SzQyMTFoV1ZfTlFuUlJWVllfQjlBamxPaU56MlRpNVRhY2p2bzZRc2hrNGdOTl94dHZiT3hzNDFBeGJ6ejZTN0xiRmM4YTJwNmlaMDNjQ1pRdUQyQkN6MDV6REN5dHNNUnNUeU93djduNEdvcjZab3F6alBwLUdCS19HNE1tcm5JcW5uUW10Q2Y1eHZJaXlyRDc2Rk8xNVVfdmc?oc=5", "source_name": "PR Newswire", "published_at": "2025-12-18T08:00:00+00:00", "published_display": "18 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulmatrix Announces Third Quarter 2025 Financial Results and Divestment Plan for Migraine and Inhalation Assets", "summary": "", "url": "https://news.google.com/rss/articles/CBMi-wFBVV95cUxNcllrZGpoemF0a2Z3eXd2QmVSRGstbGxnTHFwWDFMWjVHWHVEbkIteGQxU1poMzBwWHNUQkJYRnpGSTNRRjZmVWVoWEwtUUJhZmd0dDhXWDFDVFBVOE85UHRRcGQxdHRrR1ptaDVndDBsM0V6Ump2SHVxaTI1M1NNaFNsOHlpMkRQXy1GR1g5TmlFUlNUVEh5TnRQUHgyaUJCWTYyeFU4THp0TER2UkM1Z09jTWNiSHpoNWMwb2NjcGg2Vkc1LWVNT2xVY0laTWF5eGVfX0FPbWdWXzUzUDM5WExFTlF4MTBlRGZzM3hwNGtzSkpYRFV0MHA0Yw?oc=5", "source_name": "PR Newswire", "published_at": "2025-10-16T07:00:00+00:00", "published_display": "16 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulmatrix (PULM) Stock Forecast and Price Target 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMiZkFVX3lxTE9wYlRlSTVPTVhWNkVoZEZNZXc2TllrMTVaSDFITFNBQmpNRmljbEhLYkMtdGhNX2tzVXc5Y1IxejJGYVd2VXh2UEZPTWlYNHpPNmtTZVV1WUdiVVZkM2VtUWNCN1JHQQ?oc=5", "source_name": "MarketBeat", "published_at": "2024-05-11T14:40:23+00:00", "published_display": "11 May 2024 14:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulmatrix (PULM) Stock News & Updates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiTkFVX3lxTE9ERzVpNFRGVFUtTEpZX2FJZUEwMG9iU2VZeTdlaEZGN3M3cmU4UzRETVU3bUR4cEpHeFlyYkJ0UzJfY01zYXhHNTk3Um42Zw?oc=5", "source_name": "Stock Titan", "published_at": "2020-09-16T13:04:53+00:00", "published_display": "16 Sep 2020 13:04", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulmatrix (PULM) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE1hZUNpN0FuTXZOREVxOWJXWTY1R3pwTWNhMUxjNXlSYzJESE16WUZSdFpnMnZhM2R2VEROUHcxU3d5dHc2TUFFbFFmY1QwczJnWXBYb3VzTmNLdw?oc=5", "source_name": "MarketBeat", "published_at": "2016-08-11T23:15:05+00:00", "published_display": "11 Aug 2016 23:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Pulmatrix (NASDAQ: PULM) to Merge with Eos; 75.2M Shares to Be Issued", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxQd3FkU29HOEFUbm9abjBtdURIRjdUekdlbVZ3WTZ1ZHVqR0tNZTYzZ0N2VVV0eU1sU3BwTDZRQXZKVVJ6Mlc3LXIzTkJfQmVDYld5Wk1sN3doQnN1bGo0MGJMSUVSWFdRVE01eWhsUmxIWUVPRzRvRzAxeXlTcVFBclZhalZpTmlUTC0zcVBWZy0zZVdlRktEcFNmbXNHRWdVSHFDSHZmb3NNZFlEZkpzVjVuYw?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-09T20:06:49+00:00", "published_display": "09 Jul 2026 20:06", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulmatrix | 425: Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions - moomoo", "summary": "This article states that Pulmatrix has filed under Securities Act Rule 425. This filing is in connection with various prospectuses and communications related to business combination transactions. The document itself is not provided in this snippet.", "url": "https://www.moomoo.com/news/notice/306751131/pulmatrix-425-filing-under-securities-act-rule-425-of-certain", "source_name": "Moomoo", "published_at": "2026-07-07T09:40:04", "published_display": "07 Jul 2026 09:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PULM - Pulmatrix Inc Latest SEC Filings", "summary": "This article provides the latest SEC filings and detailed financial data for Pulmatrix Inc. (PULM). It includes key financial metrics, stock performance, insider ownership, institutional ownership, and analyst recommendations, offering a comprehensive overview of the company's cu", "url": "https://finviz.com/stock?t=PULM&ta=1&p=d&ty=lf&page=16", "source_name": "Finviz", "published_at": "2026-07-06T19:39:46", "published_display": "06 Jul 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Pulmatrix, Inc. \u2013 NASDAQ:PULM", "summary": "This article displays the \"Enterprise value to EBITDA forward\" metric for Pulmatrix, Inc. (NASDAQ: PULM) on TradingView. It presents financial data for the company, noting the market status as closed with no trades. The page also provides general information about TradingView's o", "url": "https://www.tradingview.com/symbols/NASDAQ-PULM/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-07-06T00:41:23", "published_display": "06 Jul 2026 00:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulmatrix Inc Actuals & Estimates (NASDAQ:PULM)", "summary": "This article provides an overview of Pulmatrix, Inc. (NASDAQ: PULM) stock, including its current price, market capitalization, historical performance, and financial data. It highlights the company's financial results, such as net income for the last quarter, and upcoming earnings", "url": "https://www.tradingview.com/symbols/NASDAQ-PULM/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T17:39:51", "published_display": "26 Jun 2026 17:39", "sentiment": "negative", "sentiment_pct": 40, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Pulmatrix, Inc. \u2013 NASDAQ:PULM", "summary": "This article provides the \"Price to earnings forward\" value for Pulmatrix, Inc. (NASDAQ: PULM). The value itself is not displayed, but the context indicates it's a financial metric for the pharmaceutical company. The page also lists various data providers for market and reference", "url": "https://www.tradingview.com/symbols/NASDAQ-PULM/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T10:11:53", "published_display": "25 Jun 2026 10:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulmatrix Inc (PULM) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Pulmatrix Inc (PULM), focusing on its price momentum, support and resistance levels, and insights from various technical indicators and moving averages. As of June 25, 2026, PULM shows a strong price momentum score and is trading with", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-pulm/technical", "source_name": "TradingKey", "published_at": "2026-06-25T02:11:27", "published_display": "25 Jun 2026 02:11", "sentiment": "positive", "sentiment_pct": 60, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulmatrix Inc (PULM) Valuation: PE, PB & Fair Value Analysis", "summary": "The article provides a valuation analysis of Pulmatrix Inc (PULM), stating its current valuation score is 7.17, ranking 255 out of 389 in the Biotechnology & Medical Research industry. It notes the company's P/E ratio is -1.18, significantly below its recent high and above its re", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-pulm/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-19T00:39:46", "published_display": "19 Jun 2026 00:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulmatrix Inc (PULM) Financial Health: Profitability & Balance Sheet Analysis", "summary": "Pulmatrix Inc (PULM) currently has a financial score of 6.80, placing it 210th out of 388 companies in the Biotechnology & Medical Research industry. The analysis indicates robust financial status but low operating efficiency. Several key financial data points such as total asset", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-pulm/financial-health", "source_name": "TradingKey", "published_at": "2026-06-18T09:10:42", "published_display": "18 Jun 2026 09:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulmatrix Inc (PULM) Risk Assessment: Volatility, Financial Risk & Investment Risk", "summary": "This article provides a detailed risk assessment for Pulmatrix Inc (PULM), highlighting its volatility, financial risk, and investment risk. It notes the stock's beta of 1.95, indicating high sensitivity to market movements, and presents various metrics such as maximum drawdown, ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-pulm/risk-assesment", "source_name": "TradingKey", "published_at": "2026-06-18T08:18:26", "published_display": "18 Jun 2026 08:18", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulmatrix Inc (PULM) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article from TradingKey provides an earnings forecast for Pulmatrix Inc (PULM), noting that no earnings forecast score is currently available for the company. It highlights that the Biotechnology & Medical Research industry's average score is 8.13 and indicates that relevant", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-pulm/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T03:18:26", "published_display": "18 Jun 2026 03:18", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulmatrix Inc (PULM) Institutional Confidence", "summary": "Pulmatrix Inc (PULM) currently has an institutional shareholding score of 3.00, placing it 193rd out of 389 in the Biotechnology & Medical Research industry. The institutional shareholding proportion is 10.12%, an 8.89% increase quarter-over-quarter. James Simons is the largest i", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-pulm/sentiment", "source_name": "TradingKey", "published_at": "2026-06-17T23:40:29", "published_display": "17 Jun 2026 23:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulmatrix Inc (PULM) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article from TradingKey attempts to provide a revenue breakdown for Pulmatrix Inc (PULM), covering business segments, regional revenue, and profit contribution. However, it states that the relevant data has not yet been disclosed by the company. The page displays Pulmatrix I", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-pulm/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T18:08:59", "published_display": "17 Jun 2026 18:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulmatrix (NASDAQ: PULM) posts 2025 loss as Cullgen merger to give Cullgen 96.4%", "summary": "Pulmatrix, Inc. has amended its 2025 annual report, revealing a net loss of $5.162 million and zero revenue, a significant decrease from 2024 due to the conclusion of its Cipla collaboration and reduced operating expenses. The company's future hinges on its pending merger with Cu", "url": "https://www.stocktitan.net/sec-filings/PULM/10-k-a-pulmatrix-inc-amends-annual-report-520cd2089086.html", "source_name": "Stock Titan", "published_at": "2026-06-16T20:39:20", "published_display": "16 Jun 2026 20:39", "sentiment": "negative", "sentiment_pct": 19, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Preclinical data: PTC-2105 boosts lean mass; Pulmatrix (NASDAQ: PULM) merger on track", "summary": "Pulmatrix (NASDAQ: PULM) and Eos SENOLYTIX have released preclinical data for MitoXcel\u2122 geropeptide PTC-2105, showing it significantly boosts lean mass, reduces fat, and improves physical function in animal studies, with prolonged benefits compared to GLP-1 comparators. The compa", "url": "https://www.stocktitan.net/sec-filings/PULM/425-pulmatrix-inc-business-combination-communication-696513b8faa0.html", "source_name": "Stock Titan", "published_at": "2026-06-05T12:08:47", "published_display": "05 Jun 2026 12:08", "sentiment": "positive", "sentiment_pct": 67, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulmatrix (PULM) registers 490,910 shares for resale including 36,364 dividends", "summary": "Pulmatrix, Inc. (PULM) has registered 490,910 shares of Common Stock for resale, including 36,364 Dividend Shares, stemming from the conversion of 1,000 Series B Convertible Preferred Shares. These shares, which convert at $2.20 and carry an 8% annual dividend payable in Common S", "url": "https://www.stocktitan.net/sec-filings/PULM/s-3-pulmatrix-inc-shelf-registration-statement-daa3487021cd.html", "source_name": "Stock Titan", "published_at": "2026-06-04T10:39:05", "published_display": "04 Jun 2026 10:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PULM - Pulmatrix Inc Stock Price and Quote", "summary": "This page provides a comprehensive overview of Pulmatrix Inc. (PULM) stock, including its latest stock price, financial metrics, and price performance. It also lists recent news and press releases from the company, detailing financial results, merger agreements, clinical trial up", "url": "https://finviz.com/stock?t=PULM", "source_name": "Finviz", "published_at": "2026-06-01T17:09:40", "published_display": "01 Jun 2026 17:09", "sentiment": "negative", "sentiment_pct": 38, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulmatrix Inc. (PULM) Faces Modest Decline as Stock Tests Key Support Levels - Call Flow Alert", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxONUpVZUFOajdUTHBUZGFTT3FIZGpKMWdrWTNnTDM1bVZEclBRQU1qVkRBaXRiUTVEQ2FFakxYMFNpbjVnTkhaQnJDUU1wWUFJb3lNQkdYSU9xeEl1MkJTWFI0RWQyMjZkVTN6MEZvdk42d3FNNjQ2M2ZlM0hzT011bEVCY3hETXU3eFNqNXZtN0dPTEdkWkQtVUpfUTFZS20tMnlSNzBqR01SWUw1UUpDeEVBVHRmR052?oc=5", "source_name": "dars.gov.et", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PULM: Merger with Eos SENOLYTIX announced; Q1 net loss narrows, cash at $3.3M", "summary": "Pulmatrix (PULM) has announced a merger with Eos SENOLYTIX and successfully closed a $1 million private placement. In the first quarter of 2026, the company's net loss narrowed to $1.2 million due to reduced expenses, and it reported $3.3 million in cash reserves. Clinical develo", "url": "https://www.tradingview.com/news/urn:summary_document_report:quartr.com:3335777:0-pulm-merger-with-eos-senolytix-announced-q1-net-loss-narrows-cash-at-3-3m/", "source_name": "TradingView", "published_at": "2026-05-16T09:10:53", "published_display": "16 May 2026 09:10", "sentiment": "positive", "sentiment_pct": 62, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Press Release: Pulmatrix Announces First Quarter 2026 Financial Results", "summary": "This press release from Pulmatrix announces its financial results for the first quarter of 2026. It will provide key financial figures, operational highlights, and potentially an outlook for the remainder of the year. Investors and stakeholders can expect to find details regardin", "url": "https://www.moomoo.com/news/post/70096842/press-release-pulmatrix-announces-first-quarter-2026-financial-results", "source_name": "Moomoo", "published_at": "2026-05-15T19:09:33", "published_display": "15 May 2026 19:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulmatrix Releases Q1 2026 Financial Results", "summary": "Pulmatrix, Inc. (PULM) reported a narrower loss for the first quarter of 2026, with a diluted loss per share of $0.32, showing an improvement from the prior year. The biopharmaceutical company is advancing its pipeline of inhaled therapeutic products for migraine prevention and r", "url": "https://news.alphastreet.com/pulmatrix-releases-q1-2026-financial-results/", "source_name": "AlphaStreet", "published_at": "2026-05-15T14:09:33", "published_display": "15 May 2026 14:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulmatrix Announces First Quarter 2026 Financial Results", "summary": "Pulmatrix, Inc. announced its first quarter 2026 financial results, highlighting a merger agreement with Eos SENOLYTIX and a private placement of preferred stock. The company is actively seeking to out-license or monetize its clinical assets, including iSPERSE\u2122 technology and pro", "url": "https://www.prnewswire.com/news-releases/pulmatrix-announces-first-quarter-2026-financial-results-302773027.html", "source_name": "PR Newswire", "published_at": "2026-05-15T12:09:33", "published_display": "15 May 2026 12:09", "sentiment": "positive", "sentiment_pct": 61, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulmatrix, Inc. 1Q 2026: Net loss $(1.17M), EPS $(0.32) \u2014 10-Q Summary", "summary": "Pulmatrix, Inc. reported a first-quarter 2026 net loss of $(1.17M), or $(0.32) per share, showing an improvement from the prior year. The company is undergoing a strategic merger with Eos, has paused clinical development to explore monetization options for its pipeline programs (", "url": "https://www.tradingview.com/news/tradingview:d632313770c20:0-pulmatrix-inc-1q-2026-net-loss-1-17m-eps-0-32-10-q-summary/", "source_name": "TradingView", "published_at": "2026-05-15T12:09:33", "published_display": "15 May 2026 12:09", "sentiment": "positive", "sentiment_pct": 60, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulmatrix reports Q1 2026 net loss $1.17M, cash $3.3M and announces merger agreement with Eos SENOLYTIX", "summary": "Pulmatrix reported a Q1 2026 net loss of $1.17 million and held $3.3 million in cash by March 31, 2026. The company announced a merger agreement with Eos SENOLYTIX, expected to close in Q3 2026, and a $1.0 million private placement of preferred stock. Clinical development is curr", "url": "https://www.tradingview.com/news/tradingview:fa40c9fc90de0:0-pulmatrix-reports-q1-2026-net-loss-1-17m-cash-3-3m-and-announces-merger-agreement-with-eos-senolytix/", "source_name": "TradingView", "published_at": "2026-05-15T12:09:33", "published_display": "15 May 2026 12:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulmatrix (NASDAQ: PULM) Q1 loss, $1M raise and Eos merger plan", "summary": "Pulmatrix (NASDAQ: PULM) reported a Q1 2026 net loss of $1.2 million, an improvement from $1.8 million a year prior, as operating expenses decreased. The company is actively pursuing a merger with Eos SENOLYTIX, expected to close in Q3 2026, and has raised $1.0 million through a ", "url": "https://www.stocktitan.net/sec-filings/PULM/8-k-pulmatrix-inc-reports-material-event-a44e5335ae08.html", "source_name": "Stock Titan", "published_at": "2026-05-15T12:09:33", "published_display": "15 May 2026 12:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulmatrix (PULM) Q1 2026 shows tight cash, Eos merger and 94% pro forma dilution", "summary": "Pulmatrix, Inc. (PULM) reported a Q1 2026 net loss of $1.2 million, an improvement from the previous year, primarily due to reduced operating expenses and paused R&D. The company concluded its first quarter with $3.3 million in cash and highlighted substantial doubt about its abi", "url": "https://www.stocktitan.net/sec-filings/PULM/10-q-pulmatrix-inc-quarterly-earnings-report-4c249e156f4d.html", "source_name": "Stock Titan", "published_at": "2026-05-15T12:09:33", "published_display": "15 May 2026 12:09", "sentiment": "negative", "sentiment_pct": 20, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Number of shareholders of Pulmatrix, Inc. \u2013 NASDAQ:PULM", "summary": "This article provides general financial information for Pulmatrix, Inc. (NASDAQ: PULM) as found on TradingView. It indicates that the current market status is closed and offers navigation to various financial and community features related to the company. The core content focuses", "url": "https://www.tradingview.com/symbols/NASDAQ-PULM/financials-statistics-and-ratios/number-of-shareholders/", "source_name": "TradingView", "published_at": "2026-05-10T10:39:29", "published_display": "10 May 2026 10:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulmatrix (Nasdaq:PULM) - Stock Analysis", "summary": "This Simply Wall St analysis provides an overview of Pulmatrix (PULM), a biopharmaceutical company with a market cap of US$5.0m. The report summarizes its valuation, growth prospects, past performance, financial health, and recent news including a recent acquisition agreement by ", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-pulm/pulmatrix", "source_name": "Simply Wall Street", "published_at": "2026-05-08T06:38:58", "published_display": "08 May 2026 06:38", "sentiment": "negative", "sentiment_pct": 29, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulmatrix Announces Second Quarter 2025 Financial Results and Divestment Plan for Inhalation Assets", "summary": "Pulmatrix announced its second quarter 2025 financial results and a plan to divest its inhalation assets. This news was delivered by Quantisnow, a real-time market data and news platform for retail investors. The company, trading under the symbol PULM, is in the healthcare sector", "url": "https://www.quantisnow.com/insight/pulmatrix-announces-second-quarter-2025-financial-results-and-divestment-plan-6149353", "source_name": "Quantisnow", "published_at": "2026-04-29T16:40:11", "published_display": "29 Apr 2026 16:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulmatrix closes $1M preferred stock placement with Eos affiliate By Investing.com", "summary": "Pulmatrix, Inc. (NASDAQ:PULM) has secured approximately $1 million through a private placement of Series B Convertible Preferred Stock with an affiliate of Eos SENOLYTIX, Inc. This strategic move is part of Pulmatrix's planned merger with Eos, with the preferred stock convertible", "url": "https://za.investing.com/news/company-news/pulmatrix-closes-1m-preferred-stock-placement-with-eos-affiliate-93CH-4222747", "source_name": "Investing.com South Africa", "published_at": "2026-04-26T03:38:44", "published_display": "26 Apr 2026 03:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulmatrix Announces Closing of Preferred Stock Transaction as Part of Planned Merger", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1wFBVV95cUxOMjUzb01IZUJjRlhfd2RzTlVTaURJMkIzeFpXdWl4OGs4VDFlOTZDZXUtXzc5dVJSbXlTNFFmUVZhNlduQm1POTNTTk1Mb3ZFU0t4QWlBQzZpYmI5b3dubHZWQkNVUW04cjlTQkVDUnhabWVlLUtWNWpoMmlsaUg0UXA4NVg1UkppNWljbHkyQ1R4QTJaMW9yOGdRRGdYVmkzamJnVTB2TEdTYzF0cmNHTi1BZndFQi1aZDVpcC0wYmZSZUQ3YV9wZ1JVTVNBc2hIZXhzczFCNA?oc=5", "source_name": "PR Newswire", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PULM Stock Alert: Halper Sadeh LLC is Investigating Whether Pulmatrix, Inc. is Obtaining a Fair Price for its Shareholders", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiAJBVV95cUxOY3N0NUhfT1lfUzhraXlIb1NnUUpCVHZIdndabXQ3OTlqTklJVTZHcUdkLUVVRk45dUR4YnRGUG1GVTdVR3pyWDNxbEJuMG13dmxzVmtjQ096aVI1SXRMOUNjbVVUYkw1U0c0R1BjM0RSREYyd0lVUjN3djF4b2pVcGFHd1dDY1hKalVHYWRhTl9NcHYtNWM2X0RwRV82dGVEWHdxdXczZmwxQk9YYkRUeGpTUWVkMEVGbU00UF9HM2ZKMnlCQURjRmxpR3BOM1BzM09BaFF2UF9wNWl6c3FpLXR4NXZ0V3R1NjJOSWZMeEh4SkI4S0VhSXp1RDh6LTJ2YmFYRnMxMVY?oc=5", "source_name": "Business Wire", "published_at": "2026-04-13T07:00:00+00:00", "published_display": "13 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What Just Happened to Pulmatrix (PULM) Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMigwFBVV95cUxQcHdIdDNVNk1IZV95QllwaVBZYXNzZUVmSU5yM2t6Ry1zSWxGRjB2V1dyMnBlNkFUd3ZDWTBwSklrRnk3eE1kelk4YzJYU2FKRjVNcTNZQlowUUtSd0dJbnVya1lXeDVNQ1BfTnFCZWUydE5QZFRCTlNPREhaZHFWUDJNMA?oc=5", "source_name": "Kavout | AI", "published_at": "2026-03-27T01:06:46+00:00", "published_display": "27 Mar 2026 01:06", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulmatrix and Eos SENOLYTIX Announce Merger Agreement to Advance Novel Mitochondrial Therapies to Improve Healthspan", "summary": "", "url": "https://news.google.com/rss/articles/CBMiggJBVV95cUxOdjFzWF9uT0paSHlhaHo1ZHJBWlNiQUZ4QWJIbzZmNjFkWHlxYlVGWC1xV05ZcUJiRzU3ZVJOd2FjNVBlWThGWFhNTDJoR1VPSXJiaUEwTDBOR0U4NUw4ejJGQXdMUFBUczdTbWdJeERLUWNjT3Y4X3FobkZteEYyc0NDVXQ1RTVWcnBfOGE2d1hld29udUxURFRMQXBJRzc5UFI0WkJHUEh5NVdmRWlMclZ5SUhlc3R6VVIzN3M1MlNobll2OHM4NXo0VHFCaE10SDFxRlhmSy1wUWFhRlE3akdDNkNRbnpsdUhhUVVFSGlDa0gyWXZkWUtpQi1EYTY5Snc?oc=5", "source_name": "PR Newswire", "published_at": "2026-03-26T07:00:00+00:00", "published_display": "26 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulmatrix Pursues New Reverse Merger After Cullgen Termination", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3wFBVV95cUxPZW9jcG9qMDR2bTA5V2hFc25idVZKc1RJVnFMQTA0M0lMZldUR1VEMjUzckNIVXJKUGNiUEd4QWttdWhyalcxTElrMXF5di02Tnh2V29oY0U4cE45cWRhMVJ2SzNaZDhQbjFmSER1Q2xUN0Y3NnhlWkF2TFNpZ1RFZzA2WW4yZndUNEJfNGdkbDNjY1RQQ3RJSnZULWVOS2huRm5iS1VBdkpuWm51TVpJMzg1UWdmZjZOWVA2N3R2U25VU3pTdnR3MGwzYTliNFBTN082QkQwdERZYXV0d3VZ?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-03-03T08:00:00+00:00", "published_display": "03 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulmatrix Shares Dive As Privately-Held Pharma Company Chooses To Merge With Gyre Therapeutics Instead", "summary": "", "url": "https://news.google.com/rss/articles/CBMi-gFBVV95cUxNODNCTkJBNVEtWi1mQlN5ZmZFdHNmQVNBZ0VoNU0tY3dBQmtlNlFoOEFmR0J5b3ktb1pMdl80VEIwSlR6bVJETEpLQXV4UHJGM1ZuSG5yc2Jqcno1MUdPenBXa2dNdlJHZ0MxTTB6UnNlbkxidFNFbFA2cFVYYVA2R2lPRTJPUkNCMXFfRVVGb2JveTY0dmF0VDFURVA3S2RMNU41R2JzSUFtVUtDOU0xdWNHOUpOWFBPUmxaNU41cmlvUmp2OVVjUnhJcWFicGJqVEIzUDJ5d3dsWVZjRkoyUHoxckFTcmJyak1VcXctSEJFRU5ZcktzYlJR?oc=5", "source_name": "Stocktwits", "published_at": "2026-03-02T08:00:00+00:00", "published_display": "02 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulmatrix Announces Termination of Prior Planned Merger and Continues Pursuit of Alternative Merger Opportunities", "summary": "", "url": "https://news.google.com/rss/articles/CBMi_gFBVV95cUxPTEwxNXduT1NGNVVxZzJOTjhNYlpqd2xZM2ZJRUNaWnRiWnVOTGplQksyaEhQUENHd0RmaWZKWHFSS051MmJadERsWEZNVzVRSmVOcGRmNDVac2Y4UGZYM2tuejZhNGN1cHJYU3dVcFp3RDRTMlpyb1M0VkZwSnhZOEs3U0JQM0F2OW1UekZKLVB5YnlhQk1SdW1JQzBqYi1FZm12QmRzb210a2hVd255VmVCb0owSWRhcDVySC1hOVBnMUQ5Sk83SFlfLXo1V3FVRXlWLTgtWEhvYXJiOHo0TlY0UVZEX3ZMcFc1VTc5ajlsakx4MXZoVE1ua1d2QQ?oc=5", "source_name": "PR Newswire", "published_at": "2026-03-02T08:00:00+00:00", "published_display": "02 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulmatrix and Cullgen Continue to Pursue Merger While Granting Each Other Waivers to Explore Alternatives", "summary": "", "url": "https://news.google.com/rss/articles/CBMi8wFBVV95cUxNMmhpOGczUW1jV1dpUV9sVjdWVF9sM2hKN1hPWHo3a1JrTzZseHJ5MEY0X1BWRC1RQnNUc2lKc1Z6ZkVwTV94dUdjOV9lWDljR1duQTA5TGU4SzQyMTFoV1ZfTlFuUlJWVllfQjlBamxPaU56MlRpNVRhY2p2bzZRc2hrNGdOTl94dHZiT3hzNDFBeGJ6ejZTN0xiRmM4YTJwNmlaMDNjQ1pRdUQyQkN6MDV6REN5dHNNUnNUeU93djduNEdvcjZab3F6alBwLUdCS19HNE1tcm5JcW5uUW10Q2Y1eHZJaXlyRDc2Rk8xNVVfdmc?oc=5", "source_name": "PR Newswire", "published_at": "2025-12-18T08:00:00+00:00", "published_display": "18 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulmatrix Announces Third Quarter 2025 Financial Results and Divestment Plan for Migraine and Inhalation Assets", "summary": "", "url": "https://news.google.com/rss/articles/CBMi-wFBVV95cUxNcllrZGpoemF0a2Z3eXd2QmVSRGstbGxnTHFwWDFMWjVHWHVEbkIteGQxU1poMzBwWHNUQkJYRnpGSTNRRjZmVWVoWEwtUUJhZmd0dDhXWDFDVFBVOE85UHRRcGQxdHRrR1ptaDVndDBsM0V6Ump2SHVxaTI1M1NNaFNsOHlpMkRQXy1GR1g5TmlFUlNUVEh5TnRQUHgyaUJCWTYyeFU4THp0TER2UkM1Z09jTWNiSHpoNWMwb2NjcGg2Vkc1LWVNT2xVY0laTWF5eGVfX0FPbWdWXzUzUDM5WExFTlF4MTBlRGZzM3hwNGtzSkpYRFV0MHA0Yw?oc=5", "source_name": "PR Newswire", "published_at": "2025-10-16T07:00:00+00:00", "published_display": "16 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulmatrix (PULM) Stock Forecast and Price Target 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMiZkFVX3lxTE9wYlRlSTVPTVhWNkVoZEZNZXc2TllrMTVaSDFITFNBQmpNRmljbEhLYkMtdGhNX2tzVXc5Y1IxejJGYVd2VXh2UEZPTWlYNHpPNmtTZVV1WUdiVVZkM2VtUWNCN1JHQQ?oc=5", "source_name": "MarketBeat", "published_at": "2024-05-11T14:40:23+00:00", "published_display": "11 May 2024 14:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulmatrix (PULM) Stock News & Updates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiTkFVX3lxTE9ERzVpNFRGVFUtTEpZX2FJZUEwMG9iU2VZeTdlaEZGN3M3cmU4UzRETVU3bUR4cEpHeFlyYkJ0UzJfY01zYXhHNTk3Um42Zw?oc=5", "source_name": "Stock Titan", "published_at": "2020-09-16T13:04:53+00:00", "published_display": "16 Sep 2020 13:04", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulmatrix (PULM) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE1hZUNpN0FuTXZOREVxOWJXWTY1R3pwTWNhMUxjNXlSYzJESE16WUZSdFpnMnZhM2R2VEROUHcxU3d5dHc2TUFFbFFmY1QwczJnWXBYb3VzTmNLdw?oc=5", "source_name": "MarketBeat", "published_at": "2016-08-11T23:15:05+00:00", "published_display": "11 Aug 2016 23:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 90, "total_relevant": 50, "sentiment_summary": {"positive": 6, "negative": 7, "neutral": 37, "score": 49, "total": 50, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "deals", "primary_label": "Deals and strategy", "confidence": 72, "events": [{"event": "deals", "label": "Deals and strategy", "weight": 8.8, "count": 16}, {"event": "general", "label": "Market update", "weight": 8.25, "count": 15}, {"event": "earnings", "label": "Earnings", "weight": 7.7, "count": 16}, {"event": "analyst", "label": "Analyst action", "weight": 0.55, "count": 1}, {"event": "capital_return", "label": "Capital return", "weight": 0.55, "count": 1}, {"event": "guidance", "label": "Guidance", "weight": 0.55, "count": 1}], "positive_events": 6, "negative_events": 7}, "market_context": {"has_market_context": true, "latest_close": 1.72, "latest_week": "2026-07-10", "one_week_move": 0.0, "four_week_move": 22.9, "twelve_week_move": 36.5, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 1.046124, "market_dynamics_buy_signal": false, "relative_strength": -54.701279, "fair_value_gap": -51.0, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "undecided", "expectation_probability": 45.1558, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "+0.0% over one week, +22.9% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 46, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Deals and strategy", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "TradingView", "count": 8}, {"label": "Stock Titan", "count": 7}, {"label": "TradingKey", "count": 7}, {"label": "PR Newswire", "count": 6}, {"label": "Market source", "count": 5}, {"label": "Moomoo", "count": 2}, {"label": "Finviz", "count": 2}, {"label": "simplywall.st", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 42}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Earnings", "count": 16}, {"label": "Deals and strategy", "count": 16}, {"label": "Market update", "count": 15}, {"label": "Analyst action", "count": 1}, {"label": "Capital return", "count": 1}, {"label": "Guidance", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "49/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Deals and strategy", "tone": "neutral", "text": "72/100 classification confidence."}, {"label": "Company focus", "value": "42", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+0.0% over one week, +22.9% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Pulmatrix (NASDAQ: PULM) to Merge with Eos; 75.2M Shares to Be Issued"}], "updated_at": "2026-07-16T10:42:50.061883+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}